hemophilia | Symptoms, Risk Groups & Treatment Options Page 7

Painkillers

Indication: This product is used for mild to moderate pain caused by colds, such as fever, joint pain, neuralgia, headache, migraine, dysmenorrhea, etc. It is especially suitable for people who are allergic to aspirin or are not suitable for aspirin (such as patients with chickenpox, hemophilia, bleeding diseases, anticoagulant therapy, and patients with peptic ulcer, gastritis, etc.).

Manufacturer:

Shaanxi Yishengtang Pharmaceutical Co., Ltd.

Painkillers

Indication: This product is used for mild to moderate pain caused by colds, such as fever, joint pain, neuralgia, headache, migraine, dysmenorrhea, etc. It is especially suitable for people who are allergic to aspirin or are not suitable for aspirin (such as patients with chickenpox, hemophilia, bleeding diseases, anticoagulant therapy, and patients with peptic ulcer, gastritis, etc.).

Manufacturer:

Qingdao Huanghai Pharmaceutical Co., Ltd.

Painkillers

Indication: This product is used for mild to moderate pain caused by colds, such as fever, joint pain, neuralgia, headache, migraine, dysmenorrhea, etc. It is especially suitable for people who are allergic to aspirin or are not suitable for aspirin (such as patients with chickenpox, hemophilia, bleeding diseases, anticoagulant therapy, and patients with peptic ulcer, gastritis, etc.).

Manufacturer:

KPC Pharmaceuticals, Inc.

Painkillers

Indication: This product is used for mild to moderate pain caused by colds, such as fever, joint pain, neuralgia, headache, migraine, dysmenorrhea, etc. It is especially suitable for people who are allergic to aspirin or are not suitable for aspirin (such as patients with chickenpox, hemophilia, bleeding diseases, anticoagulant therapy, and patients with peptic ulcer, gastritis, etc.).

Manufacturer:

Sinopharm Group Tongjitang(Guizhou)Pharmaceutical Co., Ltd.

Recombinant Human Coagulation Factor VIIa for Injection

Indication: It is used for the following patient groups to treat bleeding episodes and prevent bleeding during surgical procedures or invasive procedures. 1. Congenital hemophilia patients with inhibitors of coagulation factor VIII or IX > 5BU; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired hemophilia patients; 4. Congenital FVII deficiency patients; 5. Thrombasthenia patients with GPⅡb-Ⅲa and/or HLA antibodies and who have been or are currently ineffective or poorly responsive to platelet transfusions.

Aminocaproic acid tablets

Indication: It is suitable for the prevention and treatment of various bleeding caused by hyperfibrinolysis. (1) Bleeding caused by trauma or surgery of organs rich in plasminogen activators such as the prostate, urethra, lungs, liver, pancreas, brain, uterus, adrenal glands, and thyroid glands, and bleeding caused by excessive amounts of tissue plasminogen activator (t-PA), streptokinase, or urokinase. (2) It can be used as an adjuvant treatment for bleeding after tooth extraction or oral surgery or menorrhagia in hemophiliacs. (3) It can be used for symptomatic treatment of various bleeding such as upper gastrointestinal bleeding, hemoptysis, idiopathic thrombocytopenic purpura, and leukemia. It has a significant effect on general chronic oozing; it has a poor effect on bleeding caused by abnormal coagulation function; and it has no hemostatic effect on severe bleeding, massive bleeding from wounds, and bleeding from cancer.

Manufacturer:

Wuxi Jiyu Shanhe Pharmaceutical Co., Ltd.

Aminocaproic acid injection

Indication: It is suitable for the prevention and treatment of various bleeding caused by hyperfibrinolysis. ⑴ Bleeding caused by trauma or surgery in organs rich in plasminogen activators such as the prostate, urethra, lungs, liver, pancreas, brain, uterus, adrenal glands, thyroid glands, and bleeding caused by excessive tissue plasminogen activator (t-PA), streptokinase or urokinase. ⑵ Late stage of disseminated intravascular coagulation (DIC) to prevent secondary hyperfibrinolysis. ⑶ It can be used as an auxiliary treatment for bleeding after tooth extraction or oral surgery or menorrhagia in hemophilia patients. ⑷ It can be used for symptomatic treatment of various bleeding such as upper gastrointestinal bleeding, hemoptysis, idiopathic thrombocytopenic purpura and leukemia. It has a significant effect on general chronic oozing; it has poor efficacy on bleeding caused by abnormal coagulation function; it is effective for severe bleeding, heavy bleeding from wounds and bleeding from cancer, etc.

Aminocaproic acid injection

Indication: It is suitable for the prevention and treatment of various bleeding caused by hyperfibrinolysis. ⑴ Bleeding caused by trauma or surgery in organs rich in plasminogen activators such as the prostate, urethra, lungs, liver, pancreas, brain, uterus, adrenal glands, thyroid glands, and bleeding caused by excessive tissue plasminogen activator (t-PA), streptokinase or urokinase. ⑵ Late stage of disseminated intravascular coagulation (DIC) to prevent secondary hyperfibrinolysis. ⑶ It can be used as an auxiliary treatment for bleeding after tooth extraction or oral surgery or menorrhagia in hemophilia patients. ⑷ It can be used for symptomatic treatment of various bleeding such as upper gastrointestinal bleeding, hemoptysis, idiopathic thrombocytopenic purpura and leukemia. It has a significant effect on general chronic oozing; it has poor efficacy on bleeding caused by abnormal coagulation function; it is effective for severe bleeding, heavy bleeding from wounds and bleeding from cancer, etc.

Human prothrombin complex

Indication: This product is mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiency including: 1. Coagulation factor II, VII, IX, and X deficiency including hemophilia B; 2. Anticoagulant overdose and vitamin K deficiency; 3. Coagulation mechanism disorders caused by liver disease; 4. Patients who are scheduled to undergo surgery due to prolonged prothrombin time due to various reasons; 5. Treatment of bleeding symptoms in patients with hemophilia A who have developed factor VIII inhibitors; 6. Reversal of bleeding induced by coumarin anticoagulants.

Human prothrombin complex

Indication: This product is mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiency including: 1. Coagulation factor II, VII, IX, and X deficiency including hemophilia B; 2. Anticoagulant overdose and vitamin K deficiency; 3. Coagulation mechanism disorders caused by liver disease; 4. Patients who are scheduled to undergo surgery due to prolonged prothrombin time due to various reasons; 5. Treatment of bleeding symptoms in patients with hemophilia A who have developed factor VIII inhibitors; 6. Reversal of bleeding induced by coumarin anticoagulants.

Manufacturer:

Nuoyi Biopharmaceutical Co., Ltd.